The Cost of Failure

The failure of clinical candidates for a variety of reasons has already been explained. From a business perspective, the cost of failure is so great that, 

It is possible to develop ways to ascertain in Phase I some efficacy data in endocrinological indications, antibiotics, antivirals, and certain cardiovascular indications. Even in CNS disease, for example in Alzheimer disease one can look for changes in attention span in older healthy volunteers in Phase I as an indicator of possible efficacy. 

Dilemmas Insurmounable Obstacles or Unachiem.ble Goals OF Own Drug Development and THE DREAMAND REALITYOF IPO 

Discovery Fallout Development Fallout Rate (60%) Rate (80-90%) 

150-300 tar gets are being worked on simultaneously several arold ones (using chemical innovation) but most arnew. This is the lequiiement with the cuwnt attrition rate 

---

Preventive maintenance includes inspection, servicing and adjustment with the objective of preventing breakdown of equipment. This is appropriate for highly critical equipment where the cost of failure is high, or where failure implies a significant negative impact on safety or the environment. This form of maintenance can be scheduled on a calendar basis (e.g. every six months) or on a service hour basis (e.g. every 5,000 running hours). 

Failure costs - Internal failure costs are essentially the cost of failures identified and rectified before the final product gets to the external customer, such as rework, scrap, design changes. External failure costs include product recall, warranty and product liability claims. 

We have already seen elements of the CA approach when considering the costs due to safety critical failures. A further insight into the way that failure costs can be estimated for non-safety critical failures is also used to support the CA methodology. Estimates for the costs of failure in this category are based on the experiences of a sample of industrial businesses and published material as follows. 

Again, this standard aligns with the costs of failure analysis below. 

The costs of failure for this Design B were subsequently reduced to a negligible amount. 

Swift, K. G., Raines, M. and Booker, J. D. 1997 Design Capability and the Costs of Failure. Proc. Instn Mech. Engrs, Part B, 211, 409-423. 

It should be clear that a complete FMEA approach is not practical for the evaluation of production facility safety systems. This is because (1) the cost of failure is not as great as for nuclear power plants or rockets, for which this technology has proven useful (2) production facility design projects cannot support the engineering cost and lead time associated with such analysis (3) regulatory bodies are not staffed to be able to critically analyze the output of an FMEA for errors in subjective judgment and most importantly, (4) there are similarities to the design of all production facilities that have allowed industry to develop a modified FME.A approach that can satisfy all these objections. 

Does increased agitator speed improve performance in the pilot plant If so, there is a potential scaleup problem. Installing a variable-speed drive with a somewhat over-sized motor can provide some scaleup insurance, the cost of which is apt to be minor compared with the cost of failure. 

In a recently completed study, DiMasi et al. have examined the average R D cost for drugs introduced into the market in the late 1990s. Data were collected on R D costs for a randomly selected sample of 68 investigational drugs from 10 multinational firms. DiMasi et al. found that the representative new product approval incurred out-of-pocket costs of over 400 million. This includes money spent in the discovery, preclinical, and clinical phases as well as an allocation for the cost of failures. 

Christopher Price, Britain, America and Rearmament in the 1930s The Cost of Failure (Basingstoke Palgrave, 2001), esp. pp.xiii, 130-1. 

More than 800 million per drug, counting the cost of failures as well as successes, asserted at least two reports done in 2001 by consultants with industry connections—and happily touted by the drug makers. 

Occasionally anecdotal data come to light on the cash outlays required for the development of specific NCEs. For example, in depositions filed for a patent infringement lawsuit, Genentech claimed it had spent 45 million to develop Protropin , its human growth hormone product, (494) and Eli Lilly certified that it had spent 16 million between 1980 and 1987 on its effort to develop its version of the drug (495). In another example, a 1980 report of the development cost of an oral systemic drug for chronic use estimated 21 million in outlays in the clinical period (226). Unfortunately, anecdotal estimates of this kind do not help verify industrywide costs, because they are self-selected and do not reflect the cost of failures or basic research. 

Another aspect of QA made apparent by Table 11.4 is that the elements categorized as Internal and External failure are fewer, but more expensive. If QA efforts in the Prevention and Appraisal categories are managed properly, the cost of failure can be avoided. 

Todinov M.T, Reliability analysis and setting reliability requirements based on the cost of failure, International Journal of Reliability, Quality and Safety Engineering, 11(3) (2004) pp. 1-27. 

Corrective maintenance performed in a long time, poorly executed, with parts made of low quality or bad. The cost of failure can he calculated with the following formula Cf is equal to the lost revenue plus extras production raw material used. 

It is often stated that absolute safety is not possible and, therefore, risks must be managed by careful risk analysis. Less often said is that there are risks for which the cost of failure is unacceptable. On the shop floor, no risk is acceptable should the improbable occur, the result is death or amputation. 

---